RNA Manufacturing Videos
-
Scale Up: Bringing Nanomedicine From The Lab To The Clinic
4/13/2022
We discuss key components and common pain points of scaling up nanomedicine production and use recent publications to walk customers through the process.
-
The Pre-IND "Diaries": What Can mRNA Makers Expect From Early FDA Engagement?
5/10/2024
Nutcracker Therapeutics’ Oreanna Thomas shares her takeaways from a pre-IND meeting for one of the company’s mRNA therapeutic candidates.
-
Advancements In LNP CMC: What Are The Current "Known Knowns"?
12/4/2024
In this Advancing RNA Live clip, Sanofi’s Sumit Luthra highlights the learnings we’ve made to-date about how our processes — both in terms of unit operations and process conditions — inform our LNP composition/heterogeneity.
-
What Have We Learned About Our LNP's Function In Vitro In 2024?
12/4/2024
BioNTech’s Ben Muir shares a high-level overview of the LNP preclinical research advances that are the most exciting/promising today — while also reminding us of a few important caveats that accompany early-stage research.
-
Tissue Specificity and Potency & Durability
9/11/2023
During this first segment of Cell & Gene Live, Major Trends in Next-Gen RNA Engineering, hosted by Cell & Gene’s Chief Editor, Erin Harris, Nathaniel Wang, CEO and Co-Founder, Replicate Bioscience and Sam Deutch, EVP of Research and Early Development at Nutcracker Therapeutics discuss the two major trends developing in the next generation RNA space. They cover how to more accurately target tissues to reduce off-target effects or to cross a therapeutic threshold for protein expression. In addition, they discussed how to improve the amount, quality, and longevity of expressed protein to expand the use cases for RNA.
-
mRNA Capabilities
3/4/2025
Discover how our advanced capabilities in Hopkinton, MA, are overcoming the challenges of large-scale RNA therapeutic manufacturing, enabling the efficient production of complex srRNA and mRNA therapies.
-
Considerations To Better Understand/Mitigate Raw Material Variability
4/24/2023
In this Bioprocess Online Live panel discussion featuring John Stubenrauch, Ph.D., Chief Operations Officer at Nutcracker Therapeutics, and Hari Pujar, Ph.D., Chief Operating Officer at Tessera, explore the impact of and how to potentially mitigate issues posed by raw material variability.
-
Nanoassemblr Ignite mRNA Vaccine Demo
4/13/2022
The Ignite with NxGen Technology embodies everything that made the NanoAssemblr Platform the go-to for nanomedicine development for over 200 biopharma companies, while bringing the latest innovations developed for the cGMP system to the bench — saving time and money.
-
mRNA LNP Scale Up For GMP Vaccine Production
4/14/2022
Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.
-
Development Of COVID-19 Vaccine Production During A Pandemic
2/20/2025
See how seamless teamwork and automated electrophoresis systems ensured rapid, reliable COVID-19 vaccine production support and how their collaboration made a difference.